Phenylephrine hydrochloride (Phenylephrine HCL) is a widely used synthetic sympathomimetic amine primarily acting as an alpha-1 adrenergic receptor agonist. It is utilized medically for its vasoconstrictive properties to increase blood pressure, relieve nasal congestion, dilate pupils, and reduce swelling in various tissues.
Phenylephrine has been in clinical use for over 80 years and is available in multiple pharmaceutical formulations including oral, injectable, ophthalmic, and topical forms.
Chemical Structure
Phenylephrine is chemically described as (R)-β,3-dihydroxy-N-methylphenethylamine and is closely related structurally to adrenaline (epinephrine), differing mainly by the absence of one hydroxyl group on the phenyl ring. It is a chiral compound used as the enantiopure (R)-stereoisomer.
Its molecular formula is C9H13NO2 with a molecular weight of approximately 167.21 g/mol. The hydrochloride salt form, phenylephrine hydrochloride (C9H14ClNO2), is the most common pharmaceutical form, which is a white to off-white crystalline powder with a melting point around 140–171°C depending on the source.
Phenylephrine is hydrophilic with a log P of about -0.3, making it soluble in water and dilute acids but only slightly soluble in alcohols. It is not a catecholamine due to the absence of two hydroxyl groups on the phenyl ring, distinguishing it chemically from epinephrine and norepinephrine.
Phenylephrine-Based Medicines
Some of the top medicines containing phenylephrine hydrochloride include:
- Neo-Synephrine (nasal spray and injection)
- Vazculep (intravenous injection)
- Mydfrin (ophthalmic solution)
- Sudafed PE (oral decongestant)
- Preparation H (topical hemorrhoidal treatment)
- Paragon Bioteck Phenylephrine Ophthalmic Solution (2.5% and 10%)
- Prednefrin Forte (combination eye drops, withdrawn but notable)
- Cyclomydril (combination ophthalmic solution, withdrawn but historically significant)
Mechanism of Action
Phenylephrine acts as a selective alpha-1 adrenergic receptor agonist. By binding to alpha-1 receptors on vascular smooth muscle cells, it induces vasoconstriction, which leads to an increase in peripheral vascular resistance and subsequently elevates blood pressure.
This vasoconstriction also reduces nasal mucosal edema, making it effective as a decongestant. In ophthalmology, phenylephrine causes contraction of the dilator pupillae muscle, resulting in pupil dilation (mydriasis). The onset of action is rapid, especially when administered intravenously, typically within minutes. Reflex bradycardia may occur due to increased vagal tone following blood pressure elevation.
Pharmacokinetics
Phenylephrine has variable bioavailability depending on the route of administration. Oral bioavailability is low due to extensive first-pass metabolism. Intravenous administration results in rapid onset and short duration of action. The drug is metabolized primarily by monoamine oxidase and excreted via the kidneys. Its hydrophilic nature limits extensive tissue distribution.
Therapeutic Uses
| Indication | Formulation | Description |
|---|---|---|
| Hypotension | Intravenous injection | Used to increase blood pressure during shock or anesthesia-induced hypotension. |
| Nasal congestion | Oral and nasal spray | Relieves nasal mucosal swelling in colds and allergies. |
| Mydriasis (pupil dilation) | Ophthalmic solution | Used for diagnostic eye exams and surgeries. |
| Conjunctival vasoconstriction | Ophthalmic solution | Reduces eye redness. |
| Hemorrhoidal swelling | Topical cream | Provides local vasoconstriction to reduce swelling. |
| Off-label uses | Various | Includes treatment of priapism and local vasoconstriction during surgery. |
Side Effects
Common side effects of phenylephrine include hypertension, reflex bradycardia, headache, dizziness, and nervousness. Nasal formulations may cause local irritation or rebound congestion if overused. Ophthalmic use may cause transient stinging or burning. Serious adverse effects can include hypertensive crisis and arrhythmias, especially with intravenous use or overdose.
Drug Interactions
Phenylephrine may interact with monoamine oxidase inhibitors (MAOIs), leading to hypertensive crises. Concurrent use with other sympathomimetics or vasoconstrictors can potentiate hypertensive effects. Beta-blockers may blunt the reflex tachycardia response. Caution is advised when used with antihypertensives or drugs affecting heart rate and blood pressure.
Safety Considerations
Phenylephrine should be used cautiously in patients with hypertension, coronary artery disease, hyperthyroidism, or severe cardiovascular conditions due to its vasoconstrictive effects. Overuse of nasal formulations can cause rebound congestion. Ophthalmic solutions require careful dosing to avoid systemic absorption and cardiovascular effects. It is contraindicated in patients with known hypersensitivity to the drug.
Regulatory Status
Phenylephrine hydrochloride has been approved by the FDA since 1939 and is included in various over-the-counter (OTC) and prescription drug formulations. It is regulated as an alpha-adrenergic agonist for multiple indications including hypotension, nasal congestion, and ophthalmic use.
Some combination products containing phenylephrine have been withdrawn historically for reasons unrelated to safety or efficacy. The drug is listed under several ATC codes, reflecting its diverse clinical applications.
This comprehensive overview highlights phenylephrine hydrochloride as a versatile alpha-1 adrenergic agonist with important clinical roles in cardiovascular support, decongestion, and ophthalmology. Its pharmacological profile, safety considerations, and regulatory history underscore its established place in medical therapeutics.
